Vaccination for Escherichia coli O157:H7 in Market Ready Feedlot Cattle

Authors

• Robert E. Peterson, University of Nebraska-Lincoln
• David R. Smith, University of Nebraska-LincolnFollow
• Rodney A. Moxley, University of Nebraska-LincolnFollow
• Terry J. Klopfenstein, University of Nebraska-LincolnFollow
• Susan Hinkley, University of Nebraska-Lincoln

Date of this Version

January 2005

Comments

Published in 2005 Nebraska Beef Cattle Report. Copyright © 2004 The Board of Regents of the University of Nebraska.

Abstract

A clinical trial was conducted in summer 2003 to evaluate effects of vaccinating feedlot cattle against Type III secretory proteins of enterohemorrhagic Escherichia coli on prevalence of E. coli O157:H7 in feces. Treatments included: 1) no vaccination; 2) vaccinated once at re-implant (day 42); 3) vaccinated upon arrival (day 0) and again at re-implant (day 42); and 4) vaccinated on arrival (day 0), at day 21, and again at re-implant (day 42). Vaccination effectively reduced the proportion of feedlot cattle shedding O157 in the feces, the effect was dose-responsive, and vaccination within a pen conferred protection to unvaccinated pen-mates (herd immunity).